Vertex Pharmaceuticals, Inc. (VRTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jeffrey M. Leiden
Employees:
2,500
50 NORTHERN AVENUE, BOSTON, MA 02210
6173416393

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Data derived from most recent annual or quarterly report
Market Cap 57.99 Billion Shares Outstanding254.252 Million Avg 30-day Volume 1.513 Million
P/E Ratio0.0 Dividend Yield0.0 EPS3.3
Price to Revenue0.0 Debt to Equity0.0 EBITDA0
Price to Book Value0.0 Operating Margin0.0 Enterprise Value40.147 Billion
Current Ratio4.625 EPS Growth0 Quick Ratio4.211
1 Yr BETA 0.3995 52-week High/Low 242.99 / 176.36 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score0.0 Free Cash Flow to Firm 0
View SEC Filings from VRTX instead.

View recent insider trading info

Funds Holding VRTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VRTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SACHS BRUCE I

  • Director
13,672 2022-01-14 6

MCKENZIE DIANA

  • Director
794 2022-01-14 5

SACHDEV AMIT EVP, CHIEF PATIENT OFFICER

  • Officer
48,383 2021-11-15 8

ALTSHULER DAVID EVP, GLOBAL RESEARCH AND CSO

  • Officer
33,589 2021-11-15 7

ARBUCKLE STUART A EVP, COO

  • Officer
41,243 2021-11-15 7

SANNA BASTIANO EVP, CELL & GENETIC THERAPIES

  • Officer
32,576 2021-11-01 10

KEWALRAMANI RESHMA CEO & PRESIDENT

  • Officer
  • Director
73,754 2021-08-19 5

BHATIA SANGEETA N.

  • Director
5,191 2021-06-02 2

MCGLYNN MARGARET G

  • Director
5,787 2021-06-01 2

BOZIC CARMEN EVP AND CMO

  • Officer
32,953 2021-05-28 4

LIU JOY SVP, GENERAL COUNSEL

  • Officer
8,253 2021-05-17 3

CARNEY LLOYD

  • Director
5,401 2021-05-01 1

KEARNEY TERRENCE C

  • Director
6,067 2021-05-01 1

GARBER ALAN M

  • Director
6,067 2021-05-01 1

LEE YUCHUN

  • Director
6,067 2021-05-01 1

AMBROSE KRISTEN SVP & CHIEF ACCOUNTING OFFICER

  • Officer
1,394 2021-05-01 1

WAGNER CHARLES F JR EVP & CHIEF FINANCIAL OFFICER

  • Officer
34,679 2021-04-30 4

SILVA PAUL M SVP & CHIEF ACCOUNTING OFFICER

  • Officer
10,053 2021-02-26 6

PARINI MICHAEL EVP, CHIEF ADM, LEG & BD OFF

  • Officer
30,837 2021-02-24 6

TATSIS OURANIA EVP, CHIEF REG. & QUALITY OFF.

  • Officer
31,432 2021-02-24 4

LEIDEN JEFFREY M EXECUTIVE CHAIRMAN

  • Officer
  • Director
50,116 2021-02-17 3

YOUNG WILLIAM D

  • Director
No longer subject to file 2020-06-01 0

ULLIAN ELAINE

  • Director
0 2019-06-01 0

GRANEY THOMAS CHIEF FINANCIAL OFFICER

  • Officer
12,430 2018-10-01 0

SMITH IAN F EVP, COO

  • Officer
52,005 2018-06-29 0

CHODAKEWITZ JEFFREY EVP

  • Officer
No longer subject to file 2018-04-01 0

BOGER JOSHUA S

  • Director
No longer subject to file 2017-06-08 0

RILEY WAYNE JOSEPH

  • Director
0 2015-06-01 0

CONNOLLY THOMAS SVP, HUMAN RESOURCES

  • Officer
34,525 2014-12-12 0

HORTON KENNETH L EVP & CHIEF LEGAL OFFICER

  • Officer
72,419 2014-11-17 0

PACE MEGAN E SVP, CORP. COMMUNICATIONS

  • Officer
43,350 2014-11-17 0

MUELLER PETER EVP, GLOBAL R&D, CSO

  • Officer
169,088 2014-06-16 0

STAMOULIS CHRISTIANA SVP, CORP STRATEGY & BUS DEVLP

  • Officer
0 2013-07-30 0

KELLY LISA SVP, HUMAN RESOURCES

  • Officer
27,347 2013-02-05 0

EMMENS MATTHEW

  • Director
0 2012-06-01 0

WYSENSKI NANCY EVP, CHIEF COMMERCIAL OFFICER

  • Officer
32,232 2012-05-14 0

WINGER DENNIS L

  • Director
6,500 2012-03-09 0

HOWTON DAVID T SVP & CHIEF LEGAL OFFICER

  • Officer
19,703 2012-02-02 0

BOGER KENNETH S SVP & CHIEF LEGAL OFFICER

  • Officer
292,187 2011-09-13 0

CORDES EUGENE

  • Director
12,000 2011-03-17 0

SANDERS CHARLES A

  • Director
0 2010-06-01 0

COLLINSON STUART J

  • Director
0 2010-06-01 0

BRIMBLECOMBE ROGER W

  • Director
0 2010-03-15 0

GRAVES KURT EVP, CHIEF COMMERCIAL OFFICER

  • Officer
60,485 2009-10-19 0

GARRISON RICHARD C SVP AND CATALYST

  • Officer
38,782 2009-05-18 0

LEWIS-HALL FREDA C EVP, MEDICINES DEVELOPMENT

  • Officer
53,334 2009-03-19 0

BRANDT ERIC

  • Director
0 2009-01-29 0

ALAM JOHN J EVP, MED. DEV. GROUP & CMO

  • Officer
141,932 2008-10-01 0

POWER JOHANNA MESSINA VP & CONTROLLER

  • Officer
0 2008-07-24 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SACHS BRUCE I - Director

2022-01-19 16:24:55 -0500 2022-01-14 A 190 $230.58 a 13,672 direct

MCKENZIE DIANA - Director

2022-01-19 16:21:25 -0500 2022-01-14 A 119 $230.58 a 794 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 22:15:03 UTC -0.2499 0.3199 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 21:45:03 UTC -0.2499 0.3199 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 21:15:03 UTC -0.2499 0.3199 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 20:45:03 UTC -0.2547 0.3247 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 20:15:03 UTC -0.2547 0.3247 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 19:45:03 UTC -0.2547 0.3247 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 19:15:03 UTC -0.2547 0.3247 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 18:45:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 18:15:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 17:45:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 17:15:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 16:45:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 16:15:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 15:45:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 15:15:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 14:45:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 14:15:03 UTC -0.18 0.25 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 13:45:03 UTC -0.2468 0.3168 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 13:15:03 UTC -0.2468 0.3168 6200000
VERTEX PHARMACEUTICALS INC VRTX 2022-01-21 12:45:03 UTC -0.2468 0.3168 6200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Absolute 500 Core Fund VRTX -44.0 shares, $-10469.8 2020-03-31 N-PORT
AdvisorShares Trust- AdvisorShares Dorsey Wright Short ETF VRTX -1199.0 shares, $-217486.61 2021-09-30 N-PORT

Elevate your investments